Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Blood-Based Assay Identifies Hard-to-Detect Gastrointestinal Cancers

January 22nd 2020

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

Study Supports TKI Response as Predictor of Survival in HCC

January 21st 2019

Patients with previously untreated hepatocellular carcinoma lived twice as long if they responded to TKI therapy as compared with patients who did not achieve an objective response.

Dr. Strosberg Discusses Results for KEYNOTE-158

January 21st 2019

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC

January 20th 2019

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

Single-Agent Durvalumab Elicits Responses in MSI-H CRC

January 20th 2019

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC

January 20th 2019

Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.

Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer

January 20th 2019

The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.

Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC

January 19th 2019

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer

January 19th 2019

The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer

January 19th 2019

The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.

Dr. Molena on Challenges With Endoscopic Resection in Esophageal Cancers

January 19th 2019

Daniela Molena, MD, discusses what she believes is the Achilles heel of endoscopic resection in patients with esophageal cancer.

Analysis Sustains TAS-102 Survival Benefit in Gastric Cancer

January 19th 2019

Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.

Dr. Shroff Discusses Molecular Profiling in Cholangiocarcinoma

January 19th 2019

Rachna T. Shroff, MD, MS, discusses the importance of molecular profiling upon diagnosis in patients with cholangiocarcinoma.

Dr. Noel on the Impact of SM-88 in Pancreatic Cancer

January 19th 2019

Marcus Noel, MD, discusses the data of SM-88 and how it will impact the treatment of patients with metastatic pancreatic cancer.

Ramucirumab/Nivolumab Combo Shows Potential in Advanced Gastric Cancer

January 18th 2019

The combination of nivolumab and ramucirumab has activity in patients with previously treated advanced gastric adenocarcinoma, investigators reported at the 2019 Gastrointestinal Cancers Symposium.

Dr. Ocean on the Toxicities With SM-88 in Metastatic Pancreatic Cancer

January 18th 2019

Allyson J. Ocean, MD, discusses her experiences with SM-88 in patients with metastatic pancreatic cancer.

Pembrolizumab/Trastuzumab Induction Highly Active in HER2+ Gastric, GEJ Cancer

January 18th 2019

Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab, trastuzumab, and chemotherapy.

Pembrolizumab Shows OS Benefit in PD-L1+ Esophageal Cancer

January 18th 2019

Pembrolizumab was found to reduce the risk of death by 31% in patients with PD-L1–positive advanced or metastatic esophageal or esophageal junction carcinoma who progressed on standard therapy.

Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC

January 24th 2018

Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Napabucasin Plus Pembrolizumab Shows Early Promise in mCRC

January 23rd 2018

Combining the investigational oral cancer stem cell pathway inhibitor napabucasin with the PD-1 inhibitor pembrolizumab showed a signal of efficacy in the first 8 patients enrolled in a multicenter phase I/II trial of patients with metastatic colorectal cancer.